Home LiteratureArticle Details
PMID: 9556463 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S.

Postmenopausal hormone use and risk for colorectal cancer and adenoma.

Annals of internal medicine ·Vol. 128 ·No. 9 ·1998-05-01 ·Pages 705-12

Grodstein F, Martinez ME, Platz EA, Giovannucci E, Colditz GA, Kautzky M, Fuchs C, Stampfer MJ

Abstract

Accumulating evidence suggests that postmenopausal hormone use may decrease the risk for colorectal cancer. To examine the relation of postmenopausal hormone therapy to colorectal adenoma and cancer. Prospective cohort and nested case-control studies. Nurses' Health Study, a study of registered nurses recruited from 11 U.S. states. 59 002 postmenopausal participants in the Nurses' Health Study. Self-reported data on hormone use and cases of distal colorectal adenoma and colorectal cancer obtained from biennial questionnaires completed from 1980 to 1994. Cases of colorectal adenoma and cancer were confirmed by medical record review. 470 women developed colorectal cancer, and 838 developed distal colorectal adenomas. Current use of postmenopausal hormones was associated with a decreased risk for colorectal cancer (relative risk [RR], 0.65 [95% CI, 0.50 to 0.83]). This association was attenuated in past users (RR, 0.84 [CI, 0.67 to 1.05]) and disappeared 5 years after hormone use was discontinued (RR, 0.92 [CI, 0.70 to 1.21]). Longer duration of current use did not afford greater protection (RR with > or =5 years of use, 0.72 [CI, 0.53 to 0.96]). Even after exclusion of women who reported having screening sigmoidoscopy, the relative risk for colorectal cancer seen with current hormone use was 0.64 (CI, 0.49 to 0.82). This suggests that the apparent protection is unlikely to be due to more intensive screening among hormone users. Current users also had a lower risk for large (> or =1 cm) adenomas than did women who had never used hormones (RR, 0.74 [CI, 0.55 to 0.99]), although no overall material association was seen between colorectal adenoma and current hormone use (RR, 0.91 [CI,0.77 to 1.08]). The risk for colorectal cancer was decreased among women currently receiving postmenopausal hormone therapy, but the apparent reduction substantially diminished upon cessation of therapy. Hormone use was inversely associated with large colorectal adenomas but not small ones.

MeSH Terms
Adenoma/epidemiology Adult Body Mass Index Case-Control Studies Colorectal Neoplasms/epidemiology Estrogen Replacement Therapy Estrogens/administration & dosage Female Follow-Up Studies Humans Incidence Middle Aged Postmenopause Prospective Studies Risk Factors Sigmoidoscopy Surveys and Questionnaires Time Factors United States/epidemiology
Chemicals
Estrogens
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Grodstein F
Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Martinez M E
Platz E A
Giovannucci E
Colditz G A
Kautzky M
Fuchs C
Stampfer M J
Article Info
Journal
Annals of internal medicine
Abbr.
Ann Intern Med
ISSN
0003-4819
Published
1998-05-01
Pages
705-12
Language
English
Region
United States
NLM ID
0372351
Subset
IM
Grants
NIA NIH HHS · AG13482 · United States
NCI NIH HHS · CA40356 · United States
Corrections
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com